A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.
Introduction
Prostate cancer is a significant health problem throughout the world, being the most common male malignancy and the second leading cause of death in men after lung cancer. 1 Androgen deprivation is the standard therapy for newly diagnosed metastatic cancer and produces symptomatic improvements in 60-70% of patients, but results in only a small prolongation in both progressionfree survival and overall survival. 2 In fact, despite initially effective hormonal ablation therapy for patients with metastatic prostate carcinoma, the majority of these patients progress to a hormone refractory state, with a median survival of less than 2 years. 3 Therefore, subsequent treatment is needed for these patients.
Chemotherapy has been tested in patients with hormone-unresponsive disease. The difficulties in determining the activity of new agents in hormonoresistant prostate cancer (HRPC) are mainly related to the fact that only about 20% of patients have bidimensionally measurable disease. 4 Metastases typically occur in the bone, which is difficult to evaluate by bone scan because bone repair process and disease flares resemble progressive disease. So, the standardised response criteria commonly used in other solid tumours are inadequate. With these limits, chemotherapeutic agents have shown a response rate ranging from 15 to 30%. Clearly, survival remains the most important goal, but none of the cytotoxic agents used so far has been shown to have a significant impact on survival. 5, 6 Therefore, surrogate end points have been developed in the 1990s, such as changes in the prostate-specific antigen (PSA) serum levels and palliation. 7, 8 In fact, some patients benefit from chemotherapy, as manifested by decreased pain or improved functional status. In view of the goal of treating HRPC (palliation), it is appropriate to consider alternative end points that might substantiate the clinical benefit of chemotherapy.
The regimen of mitoxantrone and low-dose corticosteroids has been shown in phase III studies to be more effective in decreasing pain and/or narcotic requirements without, unfortunately, prolonging survival when compared with steroids alone. 9, 10 Recently, advances have been made in understanding the biology of hormone-refractory prostate carcinoma, which is elucidating potential targets for new drugs.
11
Vinorelbine is a new semisynthetic vinca-alkaloid derivative with antimicrotubular activity that has shown to be highly effective in small-cell lung cancer compared with vinblastine and vindesine 12, 13 and in hormonedependent tumours such as breast cancer.
14 Moreover, it has less neurotoxicity because it has limited effects on the axonal microtubules. Also significant is the fact that vinorelbine, as a single agent, has a documented activity in HRPC. 15, 16 In a phase II study of 37 evaluable patients, six patients received 30 mg/m 2 weekly and 31 patients received 22 mg/m 2 weekly because of dose delays due to granulocytopenia in the higher levels cohort. 15 Of 37 evaluable patients (39%), 14 had a clinical benefit response (improvement in Karnofsky Performance Status, 25% or greater improvement in Pain Visual Analog scale or at least a 50% decrease in analgesics, all lasting for a minimum of 12 weeks). Of these 14 patients, 11 were able to discontinue all analgesics. Four of these 14 patients had a concomitant reduction in serum PSA of at least 50%. Therapy was well tolerated with no unanticipated toxicity.
Therefore, taking into account the well-documented activity and the low-toxicity profile of vinorelbine, and the proven efficacy of the mitoxantrone + low-dose corticosteroids regimen, at the Aviano National Cancer Institute, we conducted a phase II trial, testing a regimen including mitoxantrone, vinorelbine and prednisone in HRPC.
Patients and methods

Study design
Patients with metastatic HRPC were enrolled in this study. Written informed consent was obtained, in accordance with institutional guidelines. Patients were required to have a histological diagnosis of metastatic HRPC with evidence of documented disease progression with increased serum PSA (twice as nadir), with two consecutive measurements taken 2 weeks apart and/or an increase in bidimensionally measurable soft tissue metastases or in the area of bone involvement and/or the appearance of new foci on a bone scan and/or symptomatic disease which required analgesia. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 and a life expectancy of at least 3 months. No prior chemotherapy was allowed. There was no limitation on the number of prior hormonal manipulations, but patients did have to demonstrate progressive disease after at least one hormonal treatment. All patients previously treated with an antiandrogen were required to undergo antiandrogen withdrawal. Patients were required to be off all antiandrogens for at least 4 weeks, with further evidence of disease progression after cessation of the antiandrogen.
To control the effects of androgen ablation, luteinising hormone-releasing hormone therapy was maintained. Baseline testosterone levels were not obtained. Adequate haematological function (granulocyte count41500/ mmc, platelets410 0000/mmc, haemoglobin49 g/dl), renal function (creatinine level o2x the institutional upper limit of normal) and hepatic function (serum aspartate aminotransferase o3 Â the institutional upper limit of normal, bilirubin level o1.5 Â the institutional upper limit of normal) were required at entry. Patients who had active angina, symptomatic heart failure, a history of myocardial infarction within 6 months, uncontrolled hypertension, or uncontrolled active infections were excluded. Patients had to have recovered for at least 4 weeks after radiation therapy with no radioisotope therapy within 8 weeks of entry into the study.
Therapy
Treatment was administered on an outpatient basis. The chemotherapy regimen was as follows: mitoxantrone 12 mg/m 2 i.v. day 1, vinorelbine 20 mg/m 2 i.v. day 1, prednisone 10 mg orally days 1-21. Cycles were repeated every 3 weeks. Administration of bone marrow growth factors was discouraged. Treatment was administered if granulocyte count was 41500/mmc and platelets were 4100 000/mmc. Treatment was withdrawn if one of these conditions occurred: any G4 nonhaematological toxicity, G4 haematological toxicity on day 1 of the following cycle of chemotherapy after a delay of 1 week. Oral antiemetics were prescribed for nausea as needed.
Evaluation
Each patient was screened by taking their medical history, a physical examination, an assessment of ECOG PS, complete blood cell count, serum chemistry profile, ECG, PSA determination, chest X-rays, bone scan, images of measurable disease (if appropriate), and Pain Visual Analog Score evaluation.
Complete blood cell counts were monitored weekly and serum chemistry profile and PSA determination were repeated every 3 weeks on day 1 of each chemotherapy cycle. CT scans, chest X-rays or bone scans were repeated every three cycles of chemotherapy if measurable disease was present. Pain intensity was assessed every 3 weeks, on day 1 of each chemotherapy cycle, on a 10 cm Visual Analog Scale on which 0 cm ¼ no pain and 10 cm ¼ intolerable pain. The primary objectives of this phase II study were to investigate response rate, time to progression, PSA response (450% decline) and symptom improvement. At the time the study was conducted, a response of 20% was considered low and 50% worthy of further study. This study with 24 evaluable patients had 90% power to detect an improvement from 20 to 50% in overall response rate with an one-sided alpha error of 0.05. Time to progression was measured from the time of initiation of therapy to the time progression was documented. Survival times were established from the date the patient was registered into the study until time of death or the last follow-up. Survival curves were calculated by the Kaplan-Meier method.
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Definition of response
Therapeutic effect was assessed using criteria for measurable disease, if present, change in serum PSA and pain evaluation. Owing to the difficulty of analysing efficacy of criteria, taking into account serum PSA changes, tumour response and clinical benefit, we decided to separate these parameters for response criteria.
Measurable disease. Objective response was evaluated according to World Health Organisation criteria. 17 A complete response was defined as the total disappearance of all clinically detectable disease measured by physical examination and/or radiographic studies for a period of at least 4 weeks. A partial 1 remission was defined as X50% decrease in the sum of the products of the two longest perpendicular diameters of all measurable lesions for a period of at least 4 weeks without an increase 425% in the size of any area known to contain malignant disease and without the appearance of any new areas of malignancy. Progressive disease was defined as an increase of at least 25% in the size of measurable lesions.
Serological disease. A complete serological response was defined as normalisation of PSA for two consecutive measurements taken more than 2 weeks apart and a significant PSA decline was at least a 50% decrease in PSA for two consecutive measurements taken more than 2 weeks apart. Serological progressive disease was defined as a 50% increase in PSA from the lowest level recorded and was confirmed more than 2 weeks later on the study. Stable disease was defined by a decrease in PSA o50%.
8,18
Pain evaluation. A partial response in pain intensity was defined by a 425% improvement (ie decrease) from the baseline Visual Analog Scale measurement. A progression in pain intensity was defined by 425% worsening (ie increase).
15,19
Results
Patients
From June 1998 to June 2001, 28 men with a median age of 66 years (range 55-77 years) were enrolled (Table 1) . Seven patients had measurable disease. Median PSA value was 135.5 ng/ml (range 5.2-3940 ng/ml). In all, 24 patients were fully evaluable. Two patients were administered only one cycle of chemotherapy and decided not to proceed with treatment and two patients were entered onto the study but never treated due to withdrawal of informed consent. All evaluable patients had bone metastases, while abdominal lymph nodes and supraclavicular lymph nodes were sites of metastases in six and two patients, respectively. Liver metastases were present in three patients, lung metastases in two patients. In all, 11 patients had received radiation therapy prior to entering the study and one patient had been administered intravenous radioisotope. One patient had received estramustine and one patient cisplatin + doxorubicin, but they were not excluded from analysis because of these protocol violations. ECOG PS was 0 or 1 in six and 18 patients, respectively.
Response and survival
In all, 11 patients (46%) had a significant PSA decline lasting at least 2 months. Two patients obtained a stabilisation of PSA values (8%). The median duration of the response on PSA was 11.4 months (95% CI 7.1-12.2). Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom, for a total response rate of palliation on symptoms of 62%. Median duration of the response was 9.5 months (95% CI 6.9-11.5). Out of the seven patients who had bidimensionally measurable disease, three had a confirmed partial response lasting 7 months, 10.5 months and 11 months, respectively. One patient achieved a stable disease that lasted for 4.5 months.
At the time of the present analysis, 20 patients died of disease progression and four patients are still alive. In two of the patients who died, a concomitant neoplasia was present (superficial bladder cancer in one patient and chronic lymphocytic leukaemia in one patient). Median overall survival was 11.9 months (95% CI 9.4-18.2), 1-year overall survival was 50% (95% CI 30-70), while 2-year overall survival was 17% (95% CI 1-33) (Figure 1 ). Figure 1 Overall survival of 24 patients affected by metastatic hormonoresistant prostate cancer treated with MVD.
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Toxicity
The National Cancer Institute expanded Common Toxicity Criteria (NCI-CTC) was used to evaluate patients for toxicity during each cycle. A total of 24 patients completed two or more cycles of treatment and were evaluable for toxicity (Table 2) . A total of 160 cycles of chemotherapy (median 6 cycles; range 3-13) were administered. Grade 3-4 granulocytopenia was observed in 11 patients (46%), grade 3-4 anaemia was observed in three patients (13%). In two patients, grade 2 thrombocytopenia was registered. No patients required a reduction of the dose of chemotherapy and only in 3% of the cycles there was a delay due to hematologic toxicity. Severe infection was registered in two patients; in one patient hospitalisation was necessary, and this patient discontinued treatment after three cycles of chemotherapy. Nevertheless, no lethal toxicity was seen and other nonhaematological toxicities were negligible.
Discussion
After several reports had established the activity of mitoxantrone in HRPC, Tannock et al 9 and Kantoff et al 10 demonstrated in 1996 that the combination of mitoxantrone and prednisone or hydrocortisone more reliably achieved a palliative response and for a longer duration than glucocorticoids alone. The activity of vinorelbine in HRPC has been shown in phase II trials, in terms of tumour response, PSA decline and clinical benefit criteria. In the study by Oudard et al 18 on 47 patients, six patients (17%) had a 450% decline in measured PSA values and in 23 (49%) no tumour change was observed. Clinical benefit from vinorelbine was observed in 15 of the 21 evaluable patients (32%). This clinical benefit of vinorelbine was roughly similar to the two Canadian studies on mitoxantrone, giving a palliative response in 36 and 29%, respectively. Another recent report by Fields-Jones et al 15 showed in 37 evaluable patients a 39% clinical benefit assessed by analgesic consumption and performance status.
A PSA decrease of 50% or more from the baseline has been reported to be a surrogate biologic endpoint for response. 8, 20 In our study, 11 patients (46%) had a significant PSA decline lasting at least 2 months and two patients obtained a stabilisation of PSA values (8%). The median duration of the response on PSA was 11.4 months. Eight patients achieved a palliative response, while seven patients obtained a stabilisation of pain, for a total response rate of palliation on symptoms of 62%. Median duration of the response was 9.5 months. Seven patients had bidimensionally measurable disease; three of them had a confirmed partial response lasting 7, 8 and 10.5 months, respectively. One patient achieved a stable disease that lasted for 4.5 months. The median survival of 11.9 months observed in this trial is similar to that seen in other phase II trials in HRPC.
Therapy for HPRC remains palliative and the efficacy of a regimen has to be balanced against toxicity. Our MVD schedule was given on an outpatient basis and was well tolerated. Granulocytopenia was the main toxicity, being observed in 11 patients (46%). Although two episodes of febrile neutropenia occurred in two patients, one requiring hospitalisation, there were no treatmentrelated deaths.
A phase II study that has been recently published by Sweeney et al 21 reports on a regimen consisting of vinorelbine and estramustine given in a community setting in HRPC patients. The results of this study are impressive, with a PSA response rate of 71%, a median overall survival of 15.1 months and a 1-y overall survival of 71%. However, the toxicity of oral estramustine, even if given as a short course (as in this study), is still problematic. In the Sweeney et al study, almost half of the patients required diuretic therapy and 17% had a thrombotic complication. There is an outstanding interest in regimens employing drugs that block the microtubule apparatus, especially when used in combination with estramustine. In fact, besides vinorelbine, 22, 23 several studies have combined a taxane with estramustine with encouraging results in terms of response rate and survival. [24] [25] [26] [27] However, significant toxicity was again observed in all of these studies. The thrombotic complications have been a source of concern for many investigators and have resulted in prophylactic regimens being introduced into the trials, with the aim of mitigating this toxicity. 28 The mitoxantrone-prednisone regimen has still to be considered the standard treatment for metastatic HRPC, even if a survival advantage with this regimen has not been demonstrated. With our MVD regimen, we observed a slightly better palliative effect. However, we are aware that a comparison with a multicentre phase III study was not the purpose of this phase II study. The incidence of side effects in the present study is somehow higher than that reported in previous studies, especially in terms of grade 3-4 leukopenia. This could be partially due to the fact that bone marrow growth factors could be started only when a first episode of grade 4 leukopenia was registered. On the other hand, no patients required a reduction of the dose of chemotherapy and only in 3% of the cycles there was a delay due to haematologic toxicity. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic HRPC. Our point of view is that the exploration of new regimens obtained adding antimicrotubule agents to mitoxantrone-prednisone can be a feasible and effective way to achieve better results in HRPC with low toxicity and in an outpatient setting, providing an alternative to the troublesome toxicity of estramustine. In fact, our plans are to perform a subsequent phase II trial adding docetaxel, a potent antimicrotubule agent with proven activity in HRPC, to the mitoxantrone-prednisone combination.
